Belgian IT Stock News

Argenx's Vyvgart is significantly outperforming expectations, with recent sales figures pointing to stronger than anticipated demand. The company is preparing for major Phase 3 trial readouts that are expected to clarify the potential of its broader pipeline. These developments are drawing attention from healthcare investors who view Vyvgart as an important contributor to fund performance. argenx (ENXTBR:ARGX) is drawing fresh interest as Vyvgart's performance adds weight to its current...

If you are trying to work out whether Syensqo is attractively priced or not, the recent share moves and valuation checks give you a useful starting point. Syensqo shares last closed at €78.08, with returns of 10.5% over the past 7 days, 7.1% over 30 days, 11.7% year to date and a 2.2% decline over the past year. This may point to shifting views on both upside potential and risk. Recent news coverage around Syensqo has focused on the company as a standalone listed business. This has kept...

Event context and recent return profile SCR-Sibelco (ENXTBR:094426466) has come onto investors’ radar after recent share price moves, with the stock flat over the past day, weaker over the past month, yet slightly higher across the past 3 months. This mixed return profile, alongside an intrinsic discount indicator of 11.43%, is prompting closer attention to how the company’s €2,299.814m revenue and €63.378m net income relate to current market expectations. See our latest analysis for...

Key Insights Banqup Group's significant individual investors ownership suggests that the key decisions are influenced...

Despite an already strong run, DEME Group NV ( EBR:DEME ) shares have been powering on, with a gain of 26% in the last...

Xior Student Housing (ENXTBR:XIOR) is back in focus after its 2025 earnings call, where management highlighted 5.43% like for like rental growth, 98% occupancy, and set fresh EPS growth guidance alongside new unit expansion plans. See our latest analysis for Xior Student Housing. At a share price of €28.55, Xior Student Housing has seen muted short term share price moves despite the stronger rental growth story. The 1 year total shareholder return of 3.66% decline and 5 year total shareholder...

Melexis (ENXTBR:MELE) has wrapped up FY 2025 with fourth quarter revenue of €214.5 million and basic EPS of €0.56, setting the tone for how investors might judge the year as a whole. Over recent quarters the company has seen revenue move from €197.4 million and EPS of €0.45 in Q4 2024 to a peak of €215.3 million and EPS of €0.94 in Q2 2025, before landing at the latest Q4 figures. This puts the spotlight firmly on how sustainably Melexis can support its earnings power and protect margins from...

Corona Cero, Anheuser-Busch InBev’s non-alcoholic brand, previously unveiled its TIME CERO initiative with the IOC and Athlete365, featuring a global roster of Olympian ambassadors to promote balance and mindfulness during the Olympic Winter Games. This collaboration places Corona Cero at the intersection of sports, wellness, and premium branding, potentially deepening consumer engagement with non-alcoholic offerings worldwide. We’ll now examine how Corona Cero’s Olympic-focused TIME CERO...

argenx (ENXTBR:ARGX) is back in focus after the FDA accepted priority review for an expanded Vyvgart application, alongside fresh analyst commentary pointing to strong Vyvgart sales momentum and higher long term revenue assumptions. See our latest analysis for argenx. At a share price of €717.6, argenx has seen a 4.97% 1 month share price return. Its 1 year total shareholder return of 11.92% and 3 year total shareholder return of 104.04% point to momentum that has built over a longer period,...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...

UCB has received European Union approval for Kygevi to treat thymidine kinase 2 deficiency (TK2d) in patients whose disease began before age 12, marking the first EU-authorized therapy for this rare genetic condition. The decision builds on prior FDA approval and retrospective data showing a very large reduction in risk of death versus untreated TK2d patients, underscoring Kygevi’s medical significance for a small but highly underserved population. We’ll now examine how Kygevi’s first-in-EU...

Warehouses De Pauw SA has released its full-year 2025 results, reporting sales of €451.76 million versus €398.18 million in 2024, while net income moved to €353.92 million from €435.5 million and basic earnings per share from continuing operations shifted to €1.54 from €1.96. This combination of higher revenue but lower profitability in 2025 raises questions about cost trends, portfolio mix, and how the logistics real estate group is managing its earnings profile. We’ll now examine how the...

In recent days, analysts have reiterated positive views on KBC Group, emphasizing its strong profitability, solid capital ratios, and ongoing dividends and buybacks. What stands out is how KBC’s conservative risk approach and continued investment in digital transformation are being framed as core strengths by the analyst community. We’ll now examine how this renewed focus on KBC’s disciplined capital returns shapes the company’s broader investment narrative. Rare earth metals are the new...

With a price-to-earnings (or "P/E") ratio of 13x Colruyt Group N.V. ( EBR:COLR ) may be sending bullish signals at the...

In January, argenx reported continued momentum for its autoimmune drug VYVGART, as the US FDA accepted a priority review of a supplemental biologics license application to extend its use to adults with acetylcholine receptor antibody‑seronegative generalized myasthenia gravis, while the franchise continued to post strong global sales growth in 2025. This combination of regulatory progress and broader clinical ambitions, spanning indications like immune thrombocytopenia, myositis and...

Warehouses De Pauw (ENXTBR:WDP) has wrapped up FY 2025 with fourth quarter revenue of €135.6 million and basic EPS of €0.46. This sits against a trailing 12 month picture that includes €545.8 million of revenue and EPS of €1.54. Over recent periods, revenue has moved from €116.1 million and EPS of €0.57 in Q4 2024 to €135.6 million and EPS of €0.46 in Q4 2025. The trailing 12 month net profit margin is reported at 71.4% for the latest year compared with 61.5% a year earlier, and that margin...

What stands out in Anheuser-Busch InBev’s recent performance Anheuser-Busch InBev (ENXTBR:ABI) has drawn fresh attention after a solid run in its shares, with recent returns over the past month and past 3 months prompting closer scrutiny of its fundamentals. For context, the stock shows a 0.7% return over 1 day, 2.0% over 7 days, 9.4% over the past month and 13.6% over the past 3 months. Over longer periods, the company reports a 10.4% year to date return, 27.8% 1 year total return, 13.1% 3...

If you are wondering whether SCR-Sibelco is attractively priced right now, this article explains what the current market price might be implying about its value. The stock last closed at €4,800.00, with a flat 7 day return, an 11.9% decline over the past 30 days and year to date, and a 3.0% return over the past year, which raises questions about how risk and opportunity are being priced in. Recent attention on SCR-Sibelco has focused on its share price moves and how investors interpret the...

If you are wondering whether Anheuser-Busch InBev is still reasonably priced or already fully valued, the recent share performance gives you a good starting point but not the full story. The stock last closed at €59.64, with returns of 0.5% over 7 days, 8.6% over 30 days, 9.6% year to date, 26.4% over 1 year, 12.1% over 3 years and 14.7% over 5 years. This naturally raises questions about how much of this is already reflected in the price. Recent coverage has focused on Anheuser-Busch InBev...

UBS Group AG has fallen below the 3% voting rights threshold in Solvay (ENXTBR:SOLB), according to recent Belgian transparency notifications. The change reflects an adjustment in UBS Group AG's shareholding that may matter for investors tracking Solvay's ownership profile. Solvay, a Belgium based chemicals group, operates in specialty materials, energy transition themes and a wide range of industrial end markets. For you as an investor, shifts in the register involving large institutions...

The Lotus Bakeries NV ( EBR:LOTB ) share price has done very well over the last month, posting an excellent gain of...

The Cmb.Tech NV ( EBR:CMBT ) share price has done very well over the last month, posting an excellent gain of 26...

Barco recently launched weConnect, a cloud-based collaborative learning platform for higher education that supports device connectivity, remote participation, and teacher moderation through a simple web app. The move highlights how Barco is targeting digitally enabled, student-centric learning environments, positioning its technology more directly within the evolving education-technology ecosystem. We will now explore how the higher-education focus of weConnect could shape Barco’s broader...

VGP NV recently reported the past completion of its capped tender offer for its outstanding €500,000,000 1.625% green bonds due January 2027, accepting €100,000,000 of the €320,100,000 then outstanding and confirming that the New Issue Condition was met. This move highlights VGP’s active approach to managing its green bond liabilities and refining its capital structure through selective early repayment. Next, we will explore how this targeted €100,000,000 green bond buyback shapes VGP’s...